Opening up about patient engagement
November 9, 2021 | patient engagement
Read the third blog of the series looking at key barriers to effective patient engagement in pharma
Inspired by this year’s Patient Centricity and Engagement Conference, Philippa Pristerà uses this mini blog series to reflect on key barriers to patient engagement raised during the event, and share tips and guidance on how to overcome them, collated from her own experience and those shared by speakers from the day.
Opening up about patient engagement
Two patient advocates who spoke at the conference both described pharma as “secretive”. It seemed to stem from the lack of transparency and communication around how and when they would be engaged, and when they couldn’t be. One had recently been stopped from attending a conference tailored for healthcare providers, but no one explained to her why.
This kind of ‘blocking’ can create a feeling of secrecy and depreciates industry messages that they see ‘patients as partners’. She also made the brilliant point that pharma companies do very little to communicate the fact that patients can get involved with their work – “I see the good side of pharma, but you don’t show it!”.
Health research organisations, academic research centres and charities make ‘How to get involved’ a prominent statement on their websites. But pharma companies don’t often showcase the breadth and depth of their patient engagement activity to the public and do even less to provide easy paths for other people to get involved. There are challenges at all stages of research and medicine development, but so few of them get voiced to patient groups to help solve them.
Regulations within the pharma industry may make it difficult to maintain an open dialogue at every step of a medicine’s development. But, encouraging regular communication with patients and being open about where R&D is at, and the shared challenges that exist could be adopted by all.
Fix it by…
- Shouting about your patient engagement. You do more than people know, so open up and be transparent about the engagement activity that is going on
- Creating opportunities for people to get involved in an open and inclusive way. Let people know what issues you are facing and how they can help
- Committing time and resource to frequent communication. This includes sharing more about your research activity and issues you face, sending regular updates for shared projects, and providing a continued point of contact for ad hoc check-ups
- Providing feedback on the project so patients know their contribution makes a difference. This makes them feel valued, demonstrates a company’s commitment to act on their insights, and reinforces positive feelings that will make them more likely to engage with future work and even inspire others to do the same
Missed a post in the series? Catch-up here:
In need of further guidance?
- The Patient Focused Medicines Development team have recently launched a new quality framework that can be used as both a planning tool and assessment tool to ensure you are carrying out high-quality, meaningful engagement.
- For something less focused on medicine development or medtech, check out the UK Standards for Public Involvement, which were co-produced by a UK-wide partnership to improve the quality and consistency of public involvement in research.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
The solution: Good localisation doesn’t feel translated
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.
Healthcare information is becoming easier to access. Trust isn’t.
Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.
It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment
ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.
Where translation falls short in practice
Discover why translation alone is not enough in global clinical trials and how expert localisation improves participant understanding, trust and engagement.
Where it all began – why we developed The Experience Gap
Learn how The Experience Gap was developed to help sponsors, CROs and site teams improve clinical trial participation by identifying friction points, enhancing patient experience, and driving better recruitment and…
Cuttsy+Cuttsy launches a practical roadmap to enhance clinical trial participant experience
Cuttsy+Cuttsy has launched The Experience Gap, a practical roadmap designed to help clinical trial teams improve participant engagement, support and retention across the full study journey.
Cuttsy+Cuttsy welcomes three new experts to the team
Cuttsy+Cuttsy is happy to be welcoming three new people to the team this month.
The gap between hype and reality, what patients really say about weight loss drugs
Explore real patient conversations about weight loss drugs, uncovering challenges, support strategies, and the critical need for clear, reliable healthcare communication.
Why patient-centricity depends on site-centricity in clinical trials
Explore why patient-centricity in clinical trials relies on site-centricity, emphasising the need to design trials that empower site teams to better support patients.
From cloudy to clear: visualising complex data privacy information
Discover how clear communication principles can transform complex clinical research topics, as we conclude our Health Literacy series with a practical example on participant data transparency.